MY150519A - Imidazoquinolines with immuno-modulating properties - Google Patents

Imidazoquinolines with immuno-modulating properties

Info

Publication number
MY150519A
MY150519A MYPI20094714A MY150519A MY 150519 A MY150519 A MY 150519A MY PI20094714 A MYPI20094714 A MY PI20094714A MY 150519 A MY150519 A MY 150519A
Authority
MY
Malaysia
Prior art keywords
imidazoquinolines
immuno
modulating properties
modulating
properties
Prior art date
Application number
Other languages
English (en)
Inventor
Bonnert Roger Victor
Mcinally Thomas
Thom Stephen
Wada Hiroki
Original Assignee
Astrazeneca Ab
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39596464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY150519(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Dainippon Sumitomo Pharma Co filed Critical Astrazeneca Ab
Publication of MY150519A publication Critical patent/MY150519A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI20094714 2007-05-08 2008-05-06 Imidazoquinolines with immuno-modulating properties MY150519A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91658607P 2007-05-08 2007-05-08
US2495708P 2008-01-31 2008-01-31

Publications (1)

Publication Number Publication Date
MY150519A true MY150519A (en) 2014-01-30

Family

ID=39596464

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20094714 MY150519A (en) 2007-05-08 2008-05-06 Imidazoquinolines with immuno-modulating properties

Country Status (27)

Country Link
US (2) US8436178B2 (Direct)
EP (1) EP2155743B1 (Direct)
JP (1) JP5400763B2 (Direct)
KR (1) KR20100016289A (Direct)
CN (1) CN101687867B (Direct)
AR (1) AR066492A1 (Direct)
AU (1) AU2008247165B2 (Direct)
BR (1) BRPI0811125A2 (Direct)
CA (1) CA2686163A1 (Direct)
CL (1) CL2008001357A1 (Direct)
CO (1) CO6251247A2 (Direct)
CY (1) CY1113339T1 (Direct)
DK (1) DK2155743T3 (Direct)
EC (1) ECSP099750A (Direct)
ES (1) ES2393037T3 (Direct)
HR (1) HRP20120895T1 (Direct)
IL (1) IL201572A0 (Direct)
MX (1) MX2009011802A (Direct)
MY (1) MY150519A (Direct)
PE (1) PE20090276A1 (Direct)
PL (1) PL2155743T3 (Direct)
PT (1) PT2155743E (Direct)
RU (1) RU2475487C2 (Direct)
TW (1) TW200902529A (Direct)
UY (1) UY31069A1 (Direct)
WO (1) WO2008135791A1 (Direct)
ZA (1) ZA200907547B (Direct)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549903A (en) 2004-03-26 2010-04-30 Astrazeneca Ab 9-substituted 8-oxoadenine compound
WO2008004948A1 (en) * 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
US8063051B2 (en) 2007-03-19 2011-11-22 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators
PT2132209E (pt) * 2007-03-19 2014-04-15 Astrazeneca Ab Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
EP2138497A4 (en) * 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
PE20081887A1 (es) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
JP5400763B2 (ja) * 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
EP2170888B1 (en) * 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
UY31531A1 (es) 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
WO2009091031A1 (ja) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. アデニン化合物の製造方法
US8865896B2 (en) * 2008-01-17 2014-10-21 Astrazeneca Aktiebolag Method for preparing adenine compound
SI2268618T1 (sl) * 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
NZ588183A (en) 2008-03-24 2012-05-25 4Sc Discovery Gmbh Novel substituted imidazoquinolines
BRPI0923305B1 (pt) 2008-12-09 2019-01-22 Gilead Sciences Inc moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
BR112012004806B8 (pt) 2009-09-02 2022-10-04 Novartis Ag composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
NZ598384A (en) * 2009-09-14 2014-04-30 Gilead Sciences Inc Modulators of toll-like receptors
KR101793300B1 (ko) 2009-10-22 2017-11-02 길리애드 사이언시즈, 인코포레이티드 특히 바이러스성 감염의 치료에 유용한 퓨린 또는 데아자퓨린의 유도체
EP2507237A1 (en) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2011084725A1 (en) * 2009-12-21 2011-07-14 3M Innovative Properties Company 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
EP2651937B8 (en) 2010-12-16 2016-07-13 Sumitomo Dainippon Pharma Co., Ltd. Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
WO2012080730A1 (en) 2010-12-17 2012-06-21 Astrazeneca Ab Purine derivatives
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
RU2014112343A (ru) 2011-09-01 2015-10-10 Новартис Аг Оставы антигенов staphylococcus aureus, содержащие адъюванты
US20150030630A1 (en) 2012-03-07 2015-01-29 Novartis Ag Adjuvanted formulations of rabies virus immunogens
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
CN104159602B (zh) 2012-03-08 2017-10-24 葛兰素史密丝克莱恩生物有限公司 加强疫苗的含佐剂制剂
DK2850067T3 (da) 2012-05-18 2017-11-06 Sumitomo Dainippon Pharma Co Ltd Carboxylsyreforbindelser
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
SG11201605296SA (en) 2014-01-10 2016-07-28 Birdie Biopharmaceuticals Inc Compounds and compositions for treating her2 positive tumors
CN107074958A (zh) 2014-07-09 2017-08-18 博笛生物科技有限公司 用于治疗肿瘤的抗‑pd‑l1组合
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
PT3194401T (pt) 2014-09-16 2020-12-23 Gilead Sciences Inc Formas sólidas de modulador de recetor tipo toll
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
JP7125401B2 (ja) * 2017-01-06 2022-08-24 エフ．ホフマン－ラ ロシュ アーゲー ［（１Ｓ）－１－［（２Ｓ，４Ｒ，５Ｒ）－５－（５－アミノ－２－オキソ－チアゾロ［４，５－ｄ］ピリミジン－３－イル）－４－ヒドロキシ－テトラヒドロフラン－２－イル］プロピル］アセテートの新しい固形
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
EP3603619B1 (en) 2017-03-29 2025-08-13 Sumitomo Pharma Co., Ltd. Vaccine adjuvant formulation
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
EP3641771A4 (en) 2017-06-23 2020-12-16 Birdie Biopharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS
US12012421B2 (en) 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
WO2019048036A1 (en) 2017-09-06 2019-03-14 Biontech Ag SUBSTITUTED IMIDAZOQUINOLINES
US12012420B2 (en) 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
CN111757755A (zh) 2017-12-21 2020-10-09 大日本住友制药株式会社 包含tlr7激动剂的组合药物
WO2020022272A1 (ja) 2018-07-23 2020-01-30 公益財団法人ヒューマンサイエンス振興財団 インフルエンザワクチンを含む組成物
AU2020231822A1 (en) * 2019-03-07 2021-08-26 BioNTech SE Process for the preparation of a substituted imidazoquinoline
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
CN114761406B (zh) * 2019-12-03 2024-04-19 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物
AU2021305193A1 (en) * 2020-07-08 2023-02-09 Purdue Research Foundation Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer
US20230390409A1 (en) 2020-10-30 2023-12-07 Avacta Life Sciences Limited Fap-activated serum extended half-life therapeutic conjugates
WO2024138157A1 (en) * 2022-12-22 2024-06-27 Synovo Gmbh Novel imidazoquinolines with immunostimulatory effects

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404768L (sv) 1983-09-27 1985-03-28 Ceskoslovenska Akademie Ved 9-(aminoalkyl)-8-hydroxiadeniner och sett for deras framstellning
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL78643A0 (en) * 1985-05-02 1986-08-31 Wellcome Found Purine derivatives,their preparation and pharmaceutical compositions containing them
GB8918267D0 (en) * 1989-08-10 1990-04-25 British Aerospace Weapon systems
HU222111B1 (hu) * 1991-03-01 2003-04-28 Minnesota Mining And Manufacturing Co. 1H-imidazo[4,5-c]kinolin-származékok, ilyen vegyületeket tartalmazó gyógyászati készítmények és eljárás ezek előállítására
JPH08165292A (ja) 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
US6110923A (en) * 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
FI971413A0 (fi) 1994-10-05 1997-04-04 Chiroscience Ltd Puriini- ja guaniiniyhdisteet PNP:n estäjinä
NZ329798A (en) * 1996-07-03 1999-04-29 Japan Energy Corp Purine derivatives their tautomers and salts thereof and interferon secretion inducers, antiviral agents and anticancer drugs containing the same
ATE247654T1 (de) * 1997-11-28 2003-09-15 Sumitomo Pharma Neue heterozyklische verbindungen
JPH11180981A (ja) 1997-12-19 1999-07-06 Sumitomo Pharmaceut Co Ltd 複素環誘導体
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4160645B2 (ja) 1997-12-24 2008-10-01 大日本住友製薬株式会社 新規アデニン誘導体及びその医薬用途
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
WO2000012487A1 (en) 1998-08-27 2000-03-09 Sumitomo Pharmaceuticals Co., Ltd. Pyrimidine derivatives
JP2000159767A (ja) 1998-11-26 2000-06-13 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン誘導体の新規製造法
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) * 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
GB9924361D0 (en) * 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
US20020128264A1 (en) * 2000-07-07 2002-09-12 Taylor Eve M. Methods for treatment of conditions affected by activity of multidrug transporters
DK1334103T3 (da) * 2000-07-07 2011-04-04 Spectrum Pharmaceuticals Inc Fremgangsmåde til behandling af sygdomsfremkaldt perifer neuropati og beslægtede tilstande
US20020040032A1 (en) * 2000-07-07 2002-04-04 Glasky Michelle S. Methods for stimulation of synthesis of synaptophysin in the central nervous system
US6887880B2 (en) * 2000-11-20 2005-05-03 Millennium Pharmaceuticals, Inc. Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
SI1341791T1 (en) 2000-12-08 2005-10-31 3M Innovative Properties Company Thioether substituted imidazoquinolines
JP4331944B2 (ja) * 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
DE60230340D1 (de) * 2001-11-16 2009-01-22 3M Innovative Properties Co N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung
US20060252774A1 (en) * 2002-05-02 2006-11-09 Vatner Stephen F Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases
WO2004032829A2 (en) * 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US7754728B2 (en) 2002-09-27 2010-07-13 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound and use thereof
JP2004137157A (ja) 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
AU2004257149A1 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (TLR) antagonists
CA2537450C (en) * 2003-09-05 2012-04-17 Anadys Pharmaceuticals, Inc. Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
JP2005089334A (ja) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
NZ549903A (en) * 2004-03-26 2010-04-30 Astrazeneca Ab 9-substituted 8-oxoadenine compound
EP1728792A4 (en) * 2004-03-26 2010-12-15 Dainippon Sumitomo Pharma Co 8-OXOADENINE COMPOUND
JP2008540396A (ja) * 2005-05-04 2008-11-20 ファイザー・リミテッド 癌およびｃ型肝炎などのウイルス感染を治療するためのトール様受容体調節薬としての２−アミド−６−アミノ−８−オキソプリン誘導体
EP1908480A4 (en) 2005-06-03 2009-07-01 Riken INTERFERON-ALPHA-REGULATOR
JP2009504803A (ja) * 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒアゴニスト
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
WO2007034916A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
US20090192153A1 (en) * 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
EP1939202A4 (en) * 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW COMPOUND OF ADENINE
JPWO2007034917A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規なアデニン化合物
TW200745114A (en) * 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
WO2007034882A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2008004948A1 (en) * 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
AR061839A1 (es) * 2006-07-07 2008-09-24 Gilead Sciences Inc Compuestos y composiciones farmaceuticas que activan selectivamente a receptores tipo toll 7(tlr7), y uso de los mismos como agentes antivirales
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
HRP20110115T1 (hr) * 2007-02-19 2011-03-31 Glaxosmithkline Llc Derivati purina kao imunomodulatori
US8063051B2 (en) * 2007-03-19 2011-11-22 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators
PT2132209E (pt) * 2007-03-19 2014-04-15 Astrazeneca Ab Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
PE20081887A1 (es) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
EP2138497A4 (en) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
JP5400763B2 (ja) * 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
EP2170888B1 (en) * 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
WO2009091031A1 (ja) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. アデニン化合物の製造方法
US8865896B2 (en) * 2008-01-17 2014-10-21 Astrazeneca Aktiebolag Method for preparing adenine compound
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
UA103195C2 (uk) * 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
EP2507237A1 (en) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)

Also Published As

Publication number Publication date
TW200902529A (en) 2009-01-16
CN101687867A (zh) 2010-03-31
EP2155743A1 (en) 2010-02-24
WO2008135791A8 (en) 2009-03-26
AU2008247165A1 (en) 2008-11-13
RU2009140465A (ru) 2011-06-20
CL2008001357A1 (es) 2009-01-02
US20130225555A1 (en) 2013-08-29
AR066492A1 (es) 2009-08-26
ZA200907547B (en) 2013-04-24
IL201572A0 (en) 2010-05-31
PE20090276A1 (es) 2009-04-21
ES2393037T3 (es) 2012-12-18
RU2475487C2 (ru) 2013-02-20
CN101687867B (zh) 2013-10-02
KR20100016289A (ko) 2010-02-12
UY31069A1 (es) 2009-01-05
PT2155743E (pt) 2012-10-30
HK1138849A1 (en) 2010-09-03
BRPI0811125A2 (pt) 2017-05-09
CO6251247A2 (es) 2011-02-21
JP5400763B2 (ja) 2014-01-29
ECSP099750A (es) 2010-02-26
MX2009011802A (es) 2009-11-18
HRP20120895T1 (hr) 2012-11-30
US8436178B2 (en) 2013-05-07
US20100280001A1 (en) 2010-11-04
AU2008247165B2 (en) 2011-11-03
CA2686163A1 (en) 2008-11-13
EP2155743B1 (en) 2012-08-29
DK2155743T3 (da) 2012-11-05
PL2155743T3 (pl) 2013-01-31
JP2010526129A (ja) 2010-07-29
CY1113339T1 (el) 2016-06-22
WO2008135791A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
MY150519A (en) Imidazoquinolines with immuno-modulating properties
WO2013004995A8 (en) Pyrimidinone compounds and their use
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
TW200745040A (en) Quinoline derivatives
WO2009007390A3 (en) 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
WO2009016410A3 (en) Chemical compounds 831
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
AU2011274192A8 (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
IN2012DN03328A (Direct)
MY149731A (en) Compounds
MY156552A (en) Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
MY147890A (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
MX2012013274A (es) Novedosos derivados de la pirimidina.
MX2009013501A (es) Compuestos piperidinicos y sus usos.
WO2009013545A3 (en) Chemical compounds
MX2012008328A (es) Derivados de pirazina.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
AU2010275640A8 (en) Benzoquinolizinium salt derivatives as anticancer agents
TW200639156A (en) New compounds